期刊
PEDIATRIC ALLERGY AND IMMUNOLOGY
卷 24, 期 3, 页码 237-243出版社
WILEY
DOI: 10.1111/pai.12046
关键词
bronchiolitis; corticosteroid; eczema; rhinovirus; wheezing
资金
- Academy of Finland, Helsinki, Finland [114034, 132595]
- Finnish Medical Foundation, Helsinki, Finland
- Foundation for Paediatric Research, Helsinki, Finland
- TYKS Foundation, Turku, Finland
- Specified Government Transfers, Turku, Finland
- Maud Kuistila Memorial Foundation, Helsinki, Finland
- Tampere Tuberculosis Foundation, Tampere, Finland
- Paulo Foundation, Helsinki, Finland
- Ida Montin Foundation, Espoo, Finland
- Allergy Research Foundation, Helsinki, Finland
Background To better understand the role of human rhinovirus-associated wheeze as a risk factor for childhood recurrent wheezing, a cohort of young children experiencing their first wheezing episode was followed until school age. Methods All 111 hospitalized wheezing children (median age, 12months) were initially participated in a randomized, double-blind, placebo-controlled, parallel trial on the efficacy of oral prednisolone. In this 7-yr follow-up, risk factors for recurrent wheezing were analysed, and then, the efficacy of prednisolone was evaluated overall and in pre-specified subgroups post-hoc. The main outcome was time to recurrent wheezing. Results The strongest independent risk factor for recurrent wheezing was rhinovirus detection (hazard ratio 3.54; 95% confidence interval 1.518.30) followed by sensitization (3.47; 1.558.30, respectively) age <1yr (2.45; 1.294.65) and eczema (2.33; 1.114.90). Overall, prednisolone did not prevent recurrent wheezing. In subgroup analysis, prednisolone was associated with less recurrent wheezing in children affected by rhinovirus (0.32; 0.120.90, adjusted to sensitization, young age, viral aetiology and parental asthma) and/or with eczema (0.27; 0.080.87, adjusted respectively). Conclusions Our data strengthen the role of rhinovirus-associated wheeze as an important risk factor for recurrent wheezing and asthma in young first-time wheezing children. Prospective randomized trials on the efficacy of corticosteroids in rhinovirus-associated early wheezing are warranted. (ClinicalTrials.gov number, NCT 00494624)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据